Memphis Pharmaceuticals & Chemical Industries (EGX:MPCI)
168.11
-3.99 (-2.32%)
At close: Dec 4, 2025
EGX:MPCI Balance Sheet
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Cash & Equivalents | 844.37 | 678.63 | 519.86 | 143.53 | 83.83 | 52.6 | Upgrade
|
| Cash & Short-Term Investments | 844.37 | 678.63 | 519.86 | 143.53 | 83.83 | 52.6 | Upgrade
|
| Cash Growth | 37.98% | 30.54% | 262.20% | 71.22% | 59.38% | 12.48% | Upgrade
|
| Accounts Receivable | 342.11 | 261.89 | 338.14 | 335.75 | 78.66 | 27.92 | Upgrade
|
| Other Receivables | - | - | - | - | 40.02 | 28.3 | Upgrade
|
| Receivables | 342.11 | 261.89 | 338.14 | 335.75 | 208.19 | 140.35 | Upgrade
|
| Inventory | 357 | 452.6 | 254.53 | 221.22 | 172.55 | 160.63 | Upgrade
|
| Prepaid Expenses | - | - | - | - | 1.9 | 0.49 | Upgrade
|
| Other Current Assets | - | - | - | - | 14.14 | 4.35 | Upgrade
|
| Total Current Assets | 1,543 | 1,393 | 1,113 | 700.49 | 480.61 | 358.41 | Upgrade
|
| Property, Plant & Equipment | 91.38 | 86.9 | 86.48 | 63.5 | 54.63 | 44.49 | Upgrade
|
| Long-Term Investments | 6.49 | 6.49 | 6.49 | 6.49 | 6.49 | 6.49 | Upgrade
|
| Other Intangible Assets | 4.29 | 5.2 | 8.83 | 12.46 | 16.1 | 19.73 | Upgrade
|
| Long-Term Deferred Tax Assets | 1.23 | 1.1 | 2.72 | 2.72 | 2.47 | 2.47 | Upgrade
|
| Other Long-Term Assets | - | -0 | -0 | - | 0 | - | Upgrade
|
| Total Assets | 1,647 | 1,493 | 1,217 | 785.66 | 560.29 | 431.58 | Upgrade
|
| Accounts Payable | 327.55 | 354.6 | 639.77 | 589.12 | 461.44 | 401.98 | Upgrade
|
| Accrued Expenses | - | - | - | 12.34 | 10.15 | 9.34 | Upgrade
|
| Short-Term Debt | 21.91 | 21.91 | 67.5 | 10.98 | 4.73 | 5.36 | Upgrade
|
| Current Unearned Revenue | - | - | - | 0.09 | 0.09 | - | Upgrade
|
| Other Current Liabilities | 635.44 | 272.73 | 248.7 | 64.27 | 45.68 | 50.6 | Upgrade
|
| Total Current Liabilities | 984.9 | 649.24 | 955.97 | 676.8 | 522.08 | 467.28 | Upgrade
|
| Long-Term Debt | 67.55 | 73.03 | 109.54 | 2.34 | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 2.45 | 1.57 | 1.57 | 1.37 | Upgrade
|
| Other Long-Term Liabilities | -0 | 0 | -0 | - | - | 1.11 | Upgrade
|
| Total Liabilities | 1,052 | 722.27 | 1,068 | 680.7 | 523.65 | 469.77 | Upgrade
|
| Common Stock | 227.5 | 227.5 | 56.25 | 56.25 | 56.25 | 56.25 | Upgrade
|
| Retained Earnings | 275.39 | 539.54 | 89.34 | 45.61 | -22.7 | -97.52 | Upgrade
|
| Comprehensive Income & Other | 91.52 | 3.49 | 3.49 | 3.09 | 3.09 | 3.09 | Upgrade
|
| Shareholders' Equity | 594.41 | 770.54 | 149.08 | 104.95 | 36.64 | -38.18 | Upgrade
|
| Total Liabilities & Equity | 1,647 | 1,493 | 1,217 | 785.66 | 560.29 | 431.58 | Upgrade
|
| Total Debt | 89.46 | 94.94 | 177.04 | 13.32 | 4.73 | 5.36 | Upgrade
|
| Net Cash (Debt) | 754.91 | 583.69 | 342.81 | 130.21 | 79.1 | 47.23 | Upgrade
|
| Net Cash Growth | 61.07% | 70.27% | 163.29% | 64.62% | 67.45% | 20.02% | Upgrade
|
| Net Cash Per Share | - | 25.66 | 60.94 | 23.15 | 14.06 | - | Upgrade
|
| Filing Date Shares Outstanding | - | 22.75 | 5.63 | 5.63 | 5.63 | - | Upgrade
|
| Total Common Shares Outstanding | - | 22.75 | 5.63 | 5.63 | 5.63 | - | Upgrade
|
| Working Capital | 558.57 | 743.88 | 156.56 | 23.7 | -41.47 | -108.87 | Upgrade
|
| Book Value Per Share | - | 33.87 | 26.50 | 18.66 | 6.51 | - | Upgrade
|
| Tangible Book Value | 590.12 | 765.34 | 140.25 | 92.49 | 20.55 | -57.92 | Upgrade
|
| Tangible Book Value Per Share | - | 33.64 | 24.93 | 16.44 | 3.65 | - | Upgrade
|
| Land | - | 0.59 | 0.59 | 0.59 | 0.59 | 0.59 | Upgrade
|
| Buildings | - | 99.35 | 93.19 | 60.56 | 60.56 | 59.6 | Upgrade
|
| Machinery | - | 179.47 | 148.08 | 141.61 | 141.61 | 140.68 | Upgrade
|
| Construction In Progress | 13.23 | 11.42 | 20.05 | 38.51 | 27.54 | 16.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.